NCT04989257View on ClinicalTrials.gov

24-month Ticagrelor-based Dual-antiplatelet Therapy Versus Clopidogrel-based Dual-antiplatelet theRapy aftEr 12 Months of DrUg-eluting Stent Implantation in High isChEmic Risk Patients: P-REDUCE Trial

NANot yet recruitingINTERVENTIONAL

Enrollment

3,488

Participants

Timeline

Start Date

August 31, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

High Ischemic Risk

Interventions

DRUG

Ticagrelor-based dual-antiplatelet therapy

Aspirin with ticagrelor

DRUG

Clopidogrel-based dual-antiplatelet therapy

Aspirin with clopidogrel

Trial Locations (1)

Unknown

Severance Hospital, Yonsei University Health System, Seoul

All Listed Sponsors

lead

Yonsei University

OTHER

NCT04989257 - 24-month Ticagrelor-based Dual-antiplatelet Therapy Versus Clopidogrel-based Dual-antiplatelet theRapy aftEr 12 Months of DrUg-eluting Stent Implantation in High isChEmic Risk Patients: P-REDUCE Trial | Biotech Hunter | Biotech Hunter